rs11991713 - IADEN - SNORA72

Magnitude 2.2 · 1 study on file

Reported associations

• Pharmacogenomics and Placebo Response in a Randomized Clinical Trial in Asthma - Unknown journal (n.d.) · Unknown authors · PubMed 31557306

  ABSTRACT: Genetic variation may differentially modify drug and placebo treatment effects in randomized trials (RCTs). In asthma, although lung function and asthma control improvements are commonplace with placebo, pharmacogenomics of placebo versus drug response remains unexamined. In a GWAS of subjective and objective outcomes with placebo treatment in Childhood Asthma Management Program (CAMP) of nedocromil/budesonide versus placebo (N=604), effect estimates for lead SNPs were compared across arms. The coughing/wheezing lead SNP, rs2392165 (β=0.94; P=1.10E-07) mapped to BBS9, a gene implicated in lung development which contains a lung function expression quantitative trait locus (eQTL). The effect was attenuated with budesonide (Pinteraction=1.48E-07), but not nedocromil (Pinteraction=0

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.